By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Arrowhead Research Corporation 

1118 East Green Street

Pasadena  California  91106  U.S.A.
Phone: 626-792-5549 Fax: 626-792-5554


Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.

Key Statistics

Ownership: Public

Web Site: Arrowhead Research Corporation
Symbol: ARWR

Medical Device

Company News
Arrowhead Research Corporation (ARWR) Provides Update On IND For ARC-520 Phase 2b Study 1/12/2015 12:28:08 PM
Arrowhead Research Corporation (ARWR) Soars on Rumor of Gilead Sciences, Inc. (GILD)'s Interest 12/31/2014 6:34:56 AM
Arrowhead Research Corporation (ARWR) Files IND For RNAi Therapeutic ARC-520 To Begin Phase 2b Multiple-Dose Studies In Chronic Hepatitis B Patients 12/15/2014 9:42:45 AM
Arrowhead Research Corporation (ARWR) Appoints Patrick O’Brien As General Counsel 12/5/2014 9:24:53 AM
Arrowhead Research Corporation (ARWR) Reports Fiscal 2014 Year End Financial Results 11/26/2014 8:53:57 AM
Arrowhead Research Corporation (ARWR) To Report Fiscal 2014 Fourth Quarter And Year End Financial Results 11/19/2014 2:20:01 PM
Arrowhead Research Corporation (ARWR) Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi Therapeutic ARC-AAT 11/18/2014 12:54:02 PM
Arrowhead Research Corporation (ARWR) To Present At Upcoming Conferences 11/17/2014 4:54:16 PM
Arrowhead Research Corporation (ARWR) Issues Open Letter To Shareholders 10/9/2014 9:07:51 AM
Arrowhead Research Corporation (ARWR) To Present ARC-520 Phase 2a Data In Late-Breaking Session At American Association for Study of Liver Diseases Liver Meeting® 2014 10/8/2014 11:04:31 AM